Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Cash & Equivalents (2019 - 2025)

Pulmonx (LUNG) has disclosed Cash & Equivalents for 7 consecutive years, with $74.6 million as the latest value for Q1 2025.

  • Quarterly Cash & Equivalents rose 6.27% to $74.6 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $74.6 million through Mar 2025, up 6.27% year-over-year, with the annual reading at $70.9 million for FY2024, 15.13% down from the prior year.
  • Cash & Equivalents for Q1 2025 was $74.6 million at Pulmonx, up from $70.9 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $209.3 million in Q1 2021, with the low at $63.3 million in Q3 2024.
  • Average Cash & Equivalents over 5 years is $114.3 million, with a median of $101.7 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents surged 1188.61% in 2021, then tumbled 40.24% in 2022.
  • Over 5 years, Cash & Equivalents stood at $148.5 million in 2021, then tumbled by 31.48% to $101.7 million in 2022, then decreased by 17.88% to $83.5 million in 2023, then dropped by 15.13% to $70.9 million in 2024, then increased by 5.15% to $74.6 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $74.6 million, $70.9 million, and $63.3 million for Q1 2025, Q4 2024, and Q3 2024 respectively.